Brentuximab vedotin in Hodgkin's lymphoma

Expert Opinion on Biological Therapy

Volumn 12, Issue 10, 2012, Pages 1415-1421

  Pro, Barbara ^a   Perini, Guilherme Fleury ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

Antibodydrug conjugate; Brentuximab vedotin; CD30; Hodgkin's lymphoma; MMAE; SGN 35

Indexed keywords

BRENTUXIMAB VEDOTIN; CD30 ANTIGEN;

ANTIGEN EXPRESSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PROSTATITIS; REVIEW;

CLINICAL TRIALS AS TOPIC; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES;

EID: 84866262891     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.718328     Document Type: Review

References (31)

1. Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Available from: Http//seer.cancer.gov/csr/ 1975-2006/
2. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press; Lyon, France: 2008
3. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomized trial. Lancet 2002; 359:2065-71
4. Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin's disease: Analysis by intent to treat and development of a prognostic model. Blood 2001;97:616-23
5. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002;20:221-30
6. Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005;16:625-33
7. Clodi K, Younes A. Reed-Sternberg cells and the TNF family of receptors/ligands. Leuk Lymphoma 1997;27:195-205
8. Bartlett NL, Younes A, Carabasi MH, et al. A phase I multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+hematologic malignancies. Blood 2008;111:1848-54
9. Forero-Torres A, Leonard JP, Younes A, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009;146:171-9
10. Blum KA, Jung SH, Johnson JL, et al. Serious pulmonary toxicity in patients with Hodgkin's lymphoma treated with the anti-CD30 antibody, SGN-30, and gemcitabine, vinorelbine, and liposomal doxorubicin (GVD) is associated with a FcgammaRIIIa-158 V/F polymorphism; results from CALGB 505502. Ann Oncol 2010;21:2246-54
11. Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large cell lymphoma. J Clin Oncol 2007;25:2764-9
12. Thertulien R, Frankel AE, Evens AM, et al. A Phase I, open label, dose-escalation, multidose study of MDX-1401 (defucosylated human anti-CD30 monoclonal antibody) in patients with CD30-positive refractory/relapsed Hodgkin's lymphoma [abstract 1227]. AACR Meeting Abstracts; 2009
13. Blum KA, Smith M, Fung H, et al. Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy [abstract 8531]. J Clin Oncol 2009;27:15s
14. Bross PF, Beitz J, Gang C, et al. Approval summary: Gentuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001; 7:1490-6
15. Dubowchik GM, Firestone RA, Padilla L, et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: Model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. Bioconjug Chem 2002;13:855-69
16. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30 monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-65
17. Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drugconjugate. Clin Cancer Research. 2010;16(3):888-97
18. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD-30 positive lymphomas. N Engl J Med 2010;363:1812-21
19. Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30 positive hematologic malignancies. Clin Cancer Res 2012;18:248-55
20. Younes A, Gopal AJ, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; Epub ahead of print
21. Wagner-Johnston ND, Bartlett NL, Cashen A, et al. Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leuk Lymphoma. 2012
22. Younes A, Connors JM, Park SI, et al. Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma. ASH Annual Meeting Abstracts 2010;118:995
23. Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALBG 59804. Ann Oncol 2007;18:2615-19
24. Baetz T, Belch A, Couban S, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: A phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 2003;14:1762-7
25. Gopal AK, Press OW, Shustov AR, et al. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: A prospective multicenter phase II study by the puget sound oncology consortium. Leuk lymphoma 2010;51:1523-9
26. Moskowitz AJ, Hamlin PA, Gerecitano J, et al. Bendamustine is highly active in heavily pre-treated relapsed and refractory Hodgkin lymphoma and serves as a bridge to allogeneic stem cell transplant. Blood 2009;114:abstract 720
27. Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem- cell transplantation: Results of a phase II study. J Clin Oncol 2012; Epub ahead of print
28. Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118:5119-25
29. Johnston PB, Inwards DJ, Colgan JP, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010;85:320-4
30. Younes A, Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients with recurrent classic Hodgkin disease. ancer 003;98:310-14
31. Bartlett N, Grove LE, Kennedy DA, et al. Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: A case series. J Clin Oncol 2010;28:8062